ANTISEIZURE MEDICINES — WHAT THEY ACTUALLY DO
Antiseizure medicines are the main medical treatment used to prevent epileptic seizures.
They are often abbreviated to ASMs.
Older sources may call them:
antiepileptic drugs — AEDs
anticonvulsants
seizure medicines
Antiseizure medicine is now widely preferred because most of these medicines suppress seizures rather than curing the underlying epilepsy.
WHO estimates that appropriate use of antiseizure medicines could enable up to 70% of people with epilepsy to become seizure-free.
But there is no single “epilepsy drug”.
Different antiseizure medicines affect different parts of the electrical and chemical systems that neurons use to communicate.
First: how does a neuron send a signal?
The brain contains billions of nerve cells called neurons.
Neurons communicate using:
electrical changes across their cell membranes
ion channels that allow electrically charged particles to move into and out of cells
chemical messengers called neurotransmitters
receptors that respond to those neurotransmitters
and synapses, where signals pass between cells.
A neuron normally maintains a carefully regulated electrical state.
When it receives enough stimulation, it can generate an electrical impulse called an action potential.
That signal travels along the neuron and can cause neurotransmitters to be released at a synapse.
Those neurotransmitters then influence other neurons.
This process happens constantly throughout the nervous system.
The problem in epilepsy is not simply that the brain contains “too much electricity”.
Epileptic seizures arise when networks of neurons develop abnormal patterns of excessive or highly synchronised activity.
Antiseizure medicines interfere with processes that help those abnormal patterns develop or spread.
Excitation and inhibition
One way of understanding brain signalling is through the balance between:
excitation
and:
inhibition.
Excitatory signals make neurons more likely to fire.
Inhibitory signals make them less likely to fire.
Two particularly important neurotransmitters are:
glutamate — the major excitatory neurotransmitter in the brain
and:
GABA — gamma-aminobutyric acid — the major inhibitory neurotransmitter.
But epilepsy cannot be reduced to simply:
“too much glutamate and not enough GABA.”
Seizure generation involves complex networks, ion channels, receptors, synaptic connections, genetics and other biological processes.
Modern antiseizure medicines therefore target several different parts of this system. Peer-reviewed pharmacological reviews group many current mechanisms into four broad areas: modulation of ion channels, enhancement of GABA-mediated inhibition, reduction of excitatory glutamate signalling and modification of neurotransmitter release.
1. Sodium channels — limiting repeated electrical firing
One of the most common antiseizure mechanisms involves voltage-gated sodium channels.
Sodium channels are essential for producing electrical impulses in neurons.
They open briefly to allow sodium ions to enter the cell during an action potential.
The channel then enters an inactive state before it can become available again.
During a seizure, neurons may fire rapidly and repeatedly.
Several antiseizure medicines make sodium channels less available for this type of sustained high-frequency firing.
Examples include medicines whose important actions involve sodium channels, such as:
carbamazepine
oxcarbazepine
eslicarbazepine
phenytoin
lamotrigine
lacosamide
rufinamide
cenobamate
although some of these medicines also have other actions.
A useful feature of many sodium-channel-blocking medicines is that their effect can be use-dependent.
That means they have greater effects on channels being activated repeatedly at high frequency than on neurons firing normally at lower rates.
In simplified terms, they make it harder for neurons to keep producing the rapid repetitive electrical firing associated with seizures.
Not all sodium-channel medicines work in exactly the same way
Even medicines placed in the same broad category can interact with sodium channels differently.
Many traditional sodium-channel medicines promote what is called fast inactivation.
Lacosamide has been associated particularly with enhancement of slow inactivation.
Cenobamate has actions that include inhibition of the persistent sodium current, as well as effects on GABA signalling.
These distinctions matter scientifically because “sodium-channel blocker” is not one single mechanism.
Two drugs acting on sodium channels are not necessarily pharmacologically identical.
2. Calcium channels — influencing electrical rhythms and transmitter release
Calcium ions are involved in several important neuronal processes.
Calcium channels can affect:
electrical excitability
rhythmic firing
and release of neurotransmitters from nerve endings.
Different antiseizure medicines interact with different parts of the calcium-channel system.
T-type calcium channels and absence seizures
Ethosuximide is an important example.
One of its principal actions involves reducing T-type calcium currents in thalamic neurons.
The thalamus and cerebral cortex form interconnected networks involved in the characteristic rhythmic activity associated with typical absence seizures.
This helps explain why ethosuximide has a particularly important role in the treatment of absence seizures rather than being a universal treatment for all epilepsy.
Modern guidance reflects these seizure-specific differences. For example, NICE recommends ethosuximide as first-line treatment for absence seizures, while recommending different first-line medicines for focal seizures.
The α2δ calcium-channel subunit
Other medicines influence neurotransmitter release by binding to an auxiliary part of voltage-gated calcium channels called the α2δ subunit.
Gabapentin and pregabalin are important examples.
Despite the name gabapentin, its main antiseizure mechanism is not simply acting like GABA.
Binding to α2δ proteins alters presynaptic signalling and can reduce the release of excitatory neurotransmitters.
This illustrates why medicine names do not necessarily reveal exactly how the medicines work.
3. GABA — strengthening inhibition
Another major strategy is to strengthen signalling involving GABA.
GABA is an inhibitory neurotransmitter.
When appropriate GABA receptors are activated, neuronal firing becomes less likely.
Antiseizure medicines can strengthen GABA signalling in several different ways.
Acting directly on GABA-A receptors
Some medicines increase the effects of GABA at GABA-A receptors.
These include benzodiazepines such as:
diazepam
lorazepam
clonazepam
clobazam
midazolam
depending on the clinical situation.
Benzodiazepines act as positive allosteric modulators of GABA-A receptors.
They do not simply replace GABA.
Instead, they make the receptor respond more effectively when GABA is present.
This increases inhibitory signalling.
That mechanism is one reason benzodiazepines can act rapidly and why some are used as rescue medicines during prolonged seizures or seizure clusters.
Barbiturates such as phenobarbital also enhance GABA-A receptor activity, although their pharmacology differs from benzodiazepines.
Related Information Hub page:
Seizure Clusters and Rescue Medication
Preventing GABA from being broken down
Vigabatrin works differently.
It inhibits an enzyme called GABA transaminase, which normally helps break down GABA.
Reducing GABA breakdown increases the amount of GABA available in the brain.
So both a benzodiazepine and vigabatrin can strengthen inhibitory signalling, but they do so through completely different biological processes.
Preventing GABA reuptake
Tiagabine uses another route.
After neurotransmitters are released into a synapse, transport proteins normally help clear them away.
Tiagabine inhibits the GABA transporter GAT-1.
This slows removal of GABA from the synaptic space, allowing its inhibitory action to persist longer.
4. Glutamate — reducing excitatory communication
If GABA is an important inhibitory neurotransmitter, glutamate is the brain's principal excitatory neurotransmitter.
Glutamate acts through several different receptors.
Two important receptor families in antiseizure pharmacology are:
AMPA receptors
NMDA receptors
Some antiseizure medicines reduce glutamate-mediated excitation.
AMPA receptors
Perampanel is a selective, non-competitive antagonist of AMPA receptors.
AMPA receptors contribute to fast excitatory communication between neurons.
By reducing AMPA receptor activity, perampanel reduces excitatory synaptic transmission.
This provides a very different route to seizure suppression from blocking sodium channels or increasing GABA.
NMDA receptors
Felbamate has several pharmacological actions, one of which involves reducing signalling through NMDA-type glutamate receptors.
It also has other effects, including actions involving inhibitory signalling.
Again, this illustrates an important point:
many antiseizure medicines cannot be placed neatly into only one mechanism.
5. SV2A — changing neurotransmitter release
Some antiseizure medicines target a protein called:
synaptic vesicle protein 2A — SV2A.
Synaptic vesicles are small structures inside nerve endings that contain neurotransmitters.
When a neuron signals, these vesicles participate in releasing neurotransmitter into the synapse.
Levetiracetam and brivaracetam bind to SV2A.
Exactly how SV2A binding produces all of their clinical antiseizure effects is still being investigated, but modulation of SV2A changes synaptic vesicle function and neurotransmitter release, with an overall effect of reducing pathological neuronal excitability.
This is one of the best examples of a modern antiseizure mechanism that does not fit neatly into the older idea of simply:
blocking an ion channel
or:
increasing GABA.
6. Potassium channels — making neurons harder to excite
Potassium channels also help determine a neuron's electrical state.
Movement of potassium ions contributes to:
repolarisation after an electrical impulse
membrane stability
and how easily another action potential can occur.
Increasing particular potassium currents can therefore make neurons less excitable.
The historical antiseizure medicine retigabine — ezogabine in some countries — demonstrated this principle by opening Kv7 potassium channels.
Although retigabine itself is no longer widely used, potassium-channel modulation remains an important biological target in epilepsy research and illustrates another route by which neuronal excitability can be controlled.
7. Carbonic anhydrase
Some antiseizure medicines also inhibit enzymes called carbonic anhydrases.
These enzymes help regulate the balance between:
carbon dioxide
bicarbonate
hydrogen ions
and cellular pH.
Changing that balance can influence neuronal excitability.
Medicines with carbonic-anhydrase-inhibiting activity include:
topiramate
zonisamide
acetazolamide
among others.
For medicines such as topiramate and zonisamide, this is only part of their pharmacology rather than their entire mechanism.
Some medicines have several mechanisms at once
One of the biggest misconceptions about antiseizure medicines is that every medicine has one precise target.
Many do not.
Some are multimodal, meaning several mechanisms probably contribute to their antiseizure effect.
Valproate
Valproate is a major example.
Its actions are complex and include effects involving:
sodium channels
GABA metabolism and signalling
calcium currents
and other cellular pathways.
It therefore cannot accurately be described simply as:
“a GABA medicine”
or:
“a sodium-channel blocker.”
Its broad pharmacology is one reason it has activity against several different seizure types, although its use is also affected by important safety considerations that vary according to the individual and national prescribing regulations.
Those prescribing and reproductive-safety issues belong in the dedicated medication-choice and pregnancy pages rather than being repeated here.
Topiramate
Topiramate also has several actions.
Research describes effects involving:
voltage-gated sodium channels
GABA-A signalling
glutamate receptors
carbonic anhydrase
and possibly other ion-channel mechanisms.
Calling it a single-mechanism drug would therefore be misleading.
Cenobamate
Cenobamate is another multimodal example.
Its recognised actions include:
reducing persistent sodium currents
and positively modulating certain GABA-A receptors.
It is used in particular treatment settings for focal seizures, with licensing and availability varying internationally.
What about cannabidiol?
Cannabidiol — CBD has a more complex mechanism that is not completely understood.
Its antiseizure effects appear to involve several signalling systems rather than the cannabinoid CB1 receptor mechanism associated with THC.
Research has investigated effects involving:
intracellular calcium regulation
TRPV1 channels
GPR55 signalling
adenosine
and other neuronal systems.
Licensed purified cannabidiol is used for particular epilepsy syndromes in some countries.
That is not the same thing as assuming that commercially available CBD products are equivalent epilepsy treatments.
This subject belongs in its own treatment article rather than being expanded further here.
Planned related Information Hub page:
Cannabis, CBD and Licensed Cannabidiol Are Not the Same Thing
Some treatments target the disease pathway rather than only neuronal firing
Most conventional antiseizure medicines primarily suppress seizures.
But some modern treatments illustrate a move towards cause-specific or pathway-specific therapy.
One example is everolimus in tuberous sclerosis complex.
Tuberous sclerosis involves abnormal activity in the mTOR pathway.
Everolimus inhibits mTORC1 and can reduce seizures in appropriately selected people with tuberous sclerosis complex.
That is biologically different from giving a general sodium-channel blocker to suppress neuronal firing.
It is an example of how identifying the molecular cause of an epilepsy can sometimes open the door to more targeted treatment.
Related Information Hub page:
What Causes Epilepsy?
Do antiseizure medicines cure epilepsy?
Usually, no.
Most conventional antiseizure medicines are better understood as seizure-suppressing treatments.
They reduce the probability that the neuronal activity necessary for a seizure will develop or spread while the medicine is active in the body.
They generally do not remove the underlying cause of epilepsy.
For example, an antiseizure medicine may suppress seizures arising from:
hippocampal sclerosis
focal cortical dysplasia
a genetic epilepsy
an old brain injury
without removing that underlying condition.
This distinction is one reason the modern term antiseizure medicine is more precise than suggesting every drug is “antiepileptic” in the sense of curing epilepsy. Pharmacological reviews similarly distinguish seizure suppression from prevention of the process by which an epileptic brain develops.
Then why can someone remain seizure-free after eventually stopping medication?
This does not mean the medicine necessarily cured the epilepsy.
Several possibilities exist.
The person's epilepsy may:
naturally enter long-term remission
belong to an age-related syndrome that resolves
become much less active over time
or have a sufficiently low recurrence risk that medication withdrawal becomes reasonable.
Whether medication can eventually be reduced is therefore a separate clinical question from how the medication works while being taken.
Planned related Information Hub page:
Stopping or Reducing Antiseizure Medication
Why doesn't the same medicine work for everyone?
There are several reasons.
First, epilepsy is biologically diverse.
Different people may have abnormalities involving different:
neuronal networks
ion channels
receptors
neurotransmitter systems
genes
structural abnormalities
and disease mechanisms.
Second, medicines reach and interact with their targets differently between people.
Differences can occur in:
absorption
distribution
metabolism
elimination
interactions with other medicines
and sensitivity of the nervous system to the drug.
Third, even when researchers know a medicine's molecular target, that does not mean they can predict perfectly which individual will respond to it.
A review examining whether mechanism of action should determine antiseizure medication choice concluded that clinical evidence and individual patient characteristics remain central; mechanism alone is not yet a reliable way of predicting an individual's response.
Mechanism does not equal effectiveness
It may sound logical to think:
“If we know what is malfunctioning in the brain, we can simply choose the drug that fixes that mechanism.”
Epilepsy treatment is not yet that precise in most cases.
Knowing how a medicine works is valuable.
But clinicians generally choose treatment using evidence about:
which seizure types it treats
which epilepsy syndromes it helps
clinical-trial evidence
adverse-effect profile
interactions
other medical conditions
age and individual circumstances
and established treatment guidance.
The molecular mechanism is only one part of that decision.
NICE recommends an individualised antiseizure treatment strategy and specifically includes seizure type, epilepsy syndrome, comorbidities, medication interactions, personal circumstances and patient preferences among the relevant factors.
Planned related Information Hub page:
How Doctors Choose an Epilepsy Medicine
Why can a medicine help one seizure type but worsen another?
Epileptic seizures are generated by different brain networks.
Changing a particular ion channel or neurotransmitter system may suppress one pattern of abnormal activity while having a different effect on another.
This is why antiseizure medicines should not be considered interchangeable.
For example, current NICE guidance warns that medicines including:
carbamazepine
oxcarbazepine
phenytoin
gabapentin
pregabalin
tiagabine
and vigabatrin
can worsen certain absence or myoclonic seizures, with the exact warning depending on seizure type. Lamotrigine can also occasionally exacerbate myoclonic seizures.
That does not mean those medicines are bad epilepsy treatments.
Some are highly effective for other forms of epilepsy.
It means:
the right medicine depends partly on what type of seizure and epilepsy is being treated.
“Broad-spectrum” and “narrower-spectrum” medicines
You may sometimes hear antiseizure medicines described as:
broad-spectrum
or:
narrow-spectrum.
Broad-spectrum usually refers to medicines that have useful activity across several seizure types.
Narrower-spectrum medicines may be particularly useful for specific seizure types, especially focal seizures.
These descriptions can be helpful shorthand, but they are not enough on their own to choose treatment.
Two medicines described as broad-spectrum may still differ greatly in:
mechanisms
effectiveness for a particular syndrome
adverse effects
interactions
and suitability for an individual.
What happens after someone swallows a tablet?
The medicine first has to reach the body in a usable form.
Depending on the medicine and formulation, it is:
absorbed into the bloodstream
distributed through the body
able to reach its site of action, including the brain
metabolised to varying degrees
eventually eliminated.
The amount of medicine in the body therefore rises after a dose and falls as the drug is metabolised and removed.
This is pharmacokinetics — what the body does to the drug.
The drug's effects on receptors, ion channels and other biological targets are part of pharmacodynamics — what the drug does to the body.
Both matter in epilepsy treatment.
What is a half-life?
A medicine's half-life is the approximate time required for its concentration in the body to fall by half during the elimination phase.
Different antiseizure medicines have very different half-lives.
Half-life can influence:
how often a medicine needs to be taken
how long it takes concentrations to stabilise
how quickly levels may fall after missed doses
and how slowly some medicines need to be adjusted.
Half-life can also be altered by:
age
kidney function
liver function
pregnancy
interacting medicines
and other individual factors.
This is one reason the same dose does not always produce the same drug concentration in two different people.
What does “steady state” mean?
When a medicine is taken regularly, its concentration initially changes as repeated doses accumulate.
Eventually, for most drugs taken on a stable schedule, the amount entering the body over time roughly balances the amount being eliminated.
This is called steady state.
Steady state does not mean the blood concentration stays perfectly flat throughout the day.
Levels can still rise after a dose and fall before the next dose.
It means the overall pattern has become relatively stable under that dosing schedule.
The time required to approach steady state depends largely on the medicine's half-life.
Does everyone need antiseizure medication blood tests?
No.
Routine measurement of blood concentrations is not necessary for every antiseizure medicine or every person.
For some medicines and clinical situations, measuring the concentration can be useful.
Examples can include:
suspected toxicity
unexpected breakthrough seizures
checking whether altered pharmacokinetics may be affecting treatment
pregnancy
important medicine interactions
changes in organ function
assessing adherence in selected circumstances
or establishing an individual's useful baseline concentration.
ILAE guidance on therapeutic drug monitoring emphasises that drug levels are most useful when there is a clear clinical reason for measuring them and when the result is interpreted within the whole clinical picture.
A systematic review also found no evidence that routine drug-level monitoring for everyone is superior to treatment guided clinically, while recognising that monitoring may still be useful in selected situations.
A blood level is not a seizure-control guarantee
Laboratories may provide a reference range for some antiseizure medicines.
That does not mean:
below the range = medicine cannot work
or:
inside the range = seizures must be controlled
or:
above the range = toxicity must occur.
People differ considerably.
A concentration that gives one person excellent seizure control without adverse effects may not work for another.
Research on therapeutic drug monitoring distinguishes the laboratory population reference range from an individual's own clinically useful concentration.
This is why clinicians treat the person rather than simply trying to make a laboratory number land inside a box.
Why might the same dose produce different levels in different people?
A tablet dose is not the same thing as the concentration that ultimately reaches the body.
Drug concentrations can be influenced by:
absorption
body composition
liver metabolism
kidney function
age
genetics
pregnancy
other medicines
enzyme induction or inhibition
formulation
and timing of the blood sample.
Some antiseizure medicines also have active metabolites, while others have unusual or non-linear pharmacokinetics.
This is why adjusting medication solely from the number of milligrams taken can sometimes be misleading.
Drug interactions can alter antiseizure medicine concentrations
Some antiseizure medicines affect liver enzymes responsible for metabolising other drugs.
Some other medicines can alter the metabolism of antiseizure treatments.
This means adding or removing a drug can sometimes change the concentration of another medicine even when its prescribed dose has not changed.
Interactions can also affect:
hormonal contraception
anticoagulants
psychiatric medicines
immunosuppressants
and many other treatments.
This is substantial enough to warrant a separate article rather than being condensed into this mechanisms page.
Planned related Information Hub page:
Medication Interactions
What happens if a dose is missed?
Regular dosing is intended to maintain sufficient exposure to the medicine over time.
Missing doses can allow concentrations to fall.
How much that matters depends on factors including:
which medicine is involved
its half-life
the dose missed
how many doses were missed
the person's individual seizure susceptibility
and other circumstances.
There is no universal instruction to simply double the next dose.
Advice differs between medicines.
Planned related Information Hub page:
Missed Doses, Vomiting and Medication Timing
Why are some doses increased slowly?
Many antiseizure medicines are titrated.
This means treatment begins at a lower dose and the amount is gradually increased.
There are several possible reasons.
Gradual titration can:
improve tolerability
reduce some adverse effects
allow clinicians to find the lowest effective dose
and, for certain medicines, reduce the risk of specific serious reactions.
Different medicines require very different titration schedules.
NICE recommends individualised treatment and careful titration, particularly when medicines are being introduced or combined.
Why not simply use the maximum dose?
More drug does not automatically mean better seizure control.
As the dose increases:
seizure suppression may improve
improvement may eventually plateau
adverse effects may increase
or the medicine may still fail to control the seizures.
The useful dose is therefore the one that produces the best balance between:
effectiveness
and:
tolerability
for that person.
Current NICE guidance specifically recommends using the regimen providing the best balance between seizure reduction and tolerability when treatment trials do not produce complete seizure control.
Why are medicines often tried one at a time first?
Whenever possible, epilepsy is commonly treated initially with one antiseizure medicine.
This is called monotherapy.
Using one medicine can make it easier to determine:
whether it works
which adverse effects it causes
and whether another drug is genuinely needed.
If suitable monotherapy does not work, another medicine may be substituted or additional treatment may eventually be used.
NICE recommends monotherapy whenever possible and advises considering add-on treatment when appropriate monotherapy has been unsuccessful. WHO similarly recommends trying an alternative first-line monotherapy when initial monotherapy is unsuccessful for focal or generalised-onset seizures.
Planned related Information Hub page:
Monotherapy vs Combination Therapy
Do two medicines with different mechanisms automatically work better together?
Not necessarily.
It can be tempting to assume that combining:
one sodium-channel medicine + one GABA medicine
must be scientifically superior to combining drugs in another way.
Clinical evidence is not that simple.
Research examining mechanism-based treatment selection has found limited evidence that particular mechanism combinations reliably produce synergistic seizure control across patients.
Combination treatment therefore depends on clinical evidence and the individual person, not simply constructing a pharmacological mixture on paper.
Why can antiseizure medicines cause effects outside seizures?
The molecular systems targeted by these medicines are not used only during seizures.
Sodium channels, calcium channels, GABA receptors and neurotransmitter systems are involved in normal brain function as well.
Changing them can therefore influence functions such as:
alertness
coordination
cognition
mood
behaviour
appetite
and other physiological processes.
Different medicines have different profiles, and individual responses vary greatly.
Rather than duplicating those effects here, they belong in the dedicated article:
Planned related Information Hub page:
Antiseizure Medication Side Effects
Are newer medicines automatically better?
No.
A medicine being newer does not automatically make it:
more effective
safer for everyone
more appropriate for a particular epilepsy
or preferable to an older medicine.
Older medicines remain highly effective for some seizure types.
Newer medicines may offer advantages in selected areas such as:
interaction profile
tolerability
pharmacokinetics
novel targets
or usefulness in particular epilepsies.
The relevant question is not:
“Which medicine is newest?”
It is:
“Which treatment has the best evidence and risk–benefit profile for this person's epilepsy?”
Why are we still developing new antiseizure medicines?
Although many treatments are available, a significant group of people continue to have seizures despite appropriate medication.
This is drug-resistant epilepsy when established ILAE criteria are met.
Developing new treatments therefore involves searching for:
new ion-channel targets
different receptor systems
more selective synaptic mechanisms
disease-specific molecular pathways
genetic targets
inflammatory and immune mechanisms
and treatments that might eventually modify epilepsy itself rather than only suppressing seizures.
This distinction between antiseizure treatment and true disease modification is an important frontier in epilepsy research.
Related Information Hub page:
Drug-Resistant Epilepsy — What It Actually Means
The simplest way to think about antiseizure medicines
Different antiseizure medicines interfere with seizure generation in different ways.
Some make it harder for neurons to fire repeatedly.
Some strengthen inhibitory signalling.
Some reduce excitatory signalling.
Some change how neurotransmitters are released.
Some alter particular ion channels.
Some have several mechanisms simultaneously.
And a smaller group target biological pathways linked to particular underlying diseases.
These mechanisms include:
Sodium channels
Reducing sustained rapid neuronal firing.
Calcium channels
Changing neuronal excitability or neurotransmitter release.
GABA signalling
Strengthening inhibition.
Glutamate signalling
Reducing excitation.
SV2A
Modifying synaptic vesicle function and neurotransmitter release.
Potassium channels
Helping stabilise neuronal membrane activity.
Carbonic anhydrase and other targets
Changing additional processes that influence excitability.
But knowing the mechanism alone cannot tell us which medicine will work for one particular person.
The most important message
Antiseizure medicines do much more than simply:
“calm electrical activity in the brain.”
They act on specific parts of neuronal signalling, including:
sodium channels
calcium channels
potassium channels
GABA receptors and metabolism
glutamate receptors
synaptic vesicle proteins
neurotransmitter release
and other cellular pathways.
Some medicines act mainly through one recognised mechanism.
Others act through several.
Their overall purpose is to make the abnormal neuronal activity responsible for seizures less likely to develop, sustain itself or spread.
Most conventional antiseizure medicines control susceptibility to seizures rather than cure the underlying epilepsy.
And there is no universally best antiseizure medicine.
A medicine that works extremely well for one epilepsy may:
be ineffective for another
be unsuitable for a particular syndrome
or even aggravate certain seizure types.
That is why modern treatment is based on:
the seizure type
the epilepsy type or syndrome
the evidence for the medicine
and:
the individual person
rather than simply choosing a drug because of its mechanism of action. WHO and NICE both use seizure-specific treatment recommendations rather than one universal medicine for epilepsy.
Sources and further reading
World Health Organization — Antiseizure medicines for management of epilepsy in adults and children
Current international recommendations for antiseizure treatment of focal and generalised-onset epilepsy.
World Health Organization — Epilepsy
Global overview of epilepsy treatment and the potential for seizure freedom with appropriately selected antiseizure medication.
NICE NG217 — Epilepsies in children, young people and adults: Principles of treatment, safety, monitoring and withdrawal
UK-specific guidance emphasising individualised medication selection, monotherapy where possible, careful titration and balancing effectiveness against tolerability.
NICE NG217 — Treating epileptic seizures in children, young people and adults
UK-specific recommendations showing how medication choices differ according to seizure type and identifying medicines capable of exacerbating particular seizures.
Sills GJ, Rogawski MA — Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Peer-reviewed review of the major molecular mechanisms of antiseizure medicines, including ion channels, GABA, glutamate, SV2A and other synaptic targets.
Löscher W and colleagues — The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
Detailed peer-reviewed review of modern antiseizure pharmacology, mechanisms and clinical use.
ILAE Commission on Therapeutic Strategies — Therapeutic drug monitoring of antiepileptic drugs
ILAE position paper explaining when measuring antiseizure medicine concentrations can be clinically useful and why levels must be interpreted in context rather than treated as absolute targets.
Information reviewed: September 2026.
This page provides general educational information for an international audience. Antiseizure medicine availability, licensing, recommended uses and prescribing regulations vary between countries. Individual treatment decisions should be made with an appropriately qualified healthcare professional. Antiseizure medicines should not be stopped, started or altered suddenly without appropriate medical advice.
